GLP-1/Weight Loss

As GLP-1 weight-loss drugs reshape consumption, Daesang Corporation's 450% allulose sales surge signals a massive shift in the industrial food supply chain.

As ComPsych opens its 2026 Health at Work Awards, companies are grappling with the rising costs of GLP-1s and a demand for equitable mental health support.

Driven by fiduciary lawsuits, GLP-1 costs, and hollow transparency claims, employers are abandoning pharmacy advisors at a record pace.

As Medicare's Annual Enrollment Period begins, new data reveals that administrative complexity and rising costs are pushing seniors to skip essential medical care.

As GLP-1 drug costs soar, Virta Health proves that AI-driven, nutrition-first metabolic disease reversal isn't just good medicine—it's a profitable business.

AIRS Medical's FDA-cleared SwiftSight transforms MRI body composition into a sub-five-minute, radiation-free scan, unlocking new revenue for imaging centers.

As Resmed prepares to report its Q1 FY2027 earnings, investors are watching how the medical device giant navigates GLP-1 disruptions and AI-driven growth.

A new Real-Price Index reveals the hidden fees, dose escalators, and teaser rates in the booming GLP-1 telehealth market, sparking a transparency revolution.

As GLP-1 drugs face scrutiny for causing lean tissue loss, advanced MRI biomarkers are reshaping clinical trials and the future of metabolic medicine.

Novo Nordisk’s new data shows patients successfully switching from injectable GLP-1s to a daily pill. But what does this mean for the $100B obesity market?

With a former FDA director at the helm, Keyron is positioning its reversible metabolic implant to disrupt the massive, drug-dominated weight-loss market.

As GLP-1 drugs boom, a new ancillary market is emerging to treat their side effects. French CDMO ANJAC is building the infrastructure to power it.

As global cosmetic procedures top 35 million, a mass exodus from dermal fillers and the rise of weight-loss drugs are reshaping the aesthetic industry.

Ozari Health’s new top ranking highlights a shift toward supply chain transparency, but regulatory hurdles and hidden costs complicate the weight-loss boom.

Stitch Fix stabilized its balance sheet and hit record revenue per client, but a shrinking user base and software glitches cloud its fiscal 2027 outlook.

Novo Nordisk and Siemens Healthineers are rewriting the commercialization playbook by pairing blockbuster metabolic drugs with accessible blood diagnostics.

A $450 patent error opened Canada to generic semaglutide. Now, Novo Nordisk is using supply chain supremacy to beat back competitors and reclaim the market.

As GLP-1 prescriptions surge, mail-order pharmacies are drowning in Styrofoam. A new micro-packaging solution reveals the economics of the cold chain.

As pharma giants dominate the obesity space with GLP-1 drugs, Corbus Pharmaceuticals is betting on a different mechanism. Will its upcoming data rewrite the rules?

With a key conference appearance, OPKO Health aims to translate its deep R&D pipeline into market confidence. Will investors buy into its long-term vision?